Welcome to our dedicated page for Eledon Pharmaceuticals SEC filings (Ticker: ELDN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Eledon Pharmaceuticals SEC filings document the governance, financing and clinical-development disclosures of a clinical-stage biotechnology issuer centered on tegoprubart. Proxy materials cover shareholder voting matters, board and compensation governance, equity awards and executive compensation disclosures.
Material-event filings report operating results and financial condition, Regulation FD clinical updates, presentations and press-release exhibits related to tegoprubart programs in transplantation. The filing record also includes disclosure categories tied to material agreements, capital structure, shareholder matters and clinical or regulatory developments for the company’s anti-CD40L development strategy.
BlackRock, Inc. has filed an amended ownership report showing that it beneficially owns 3,625,824 shares of Eledon Pharmaceuticals, Inc. common stock, representing 4.6% of the outstanding class as of the event date. BlackRock reports sole voting power over 3,584,479 shares and sole dispositive power over 3,625,824 shares, with no shared voting or dispositive power.
The filing states that these securities are held by certain BlackRock business units in the ordinary course of business and are not held for the purpose of changing or influencing control of Eledon Pharmaceuticals. The filing also notes that various underlying clients and investors have rights to dividends or sale proceeds, but no single person has more than five percent of Eledon’s total outstanding common shares.
Eledon Pharmaceuticals director John McBride reported the vesting and settlement of restricted stock units into common shares. On January 10, 2026, 3,430 restricted stock units were converted into 3,430 shares of Eledon Pharmaceuticals common stock at a price of $0 per share. These RSUs had been granted on January 10, 2025 and vested 100% one year later. Following this transaction, McBride directly holds 3,430 shares of common stock.
Eledon Pharmaceuticals director Jan Hillson reported the vesting and settlement of 3,430 restricted stock units into 3,430 shares of common stock. The transaction occurred on January 10, 2026 through an option exercise coded "M" at a price of $0 per share. The RSUs were originally granted on January 10, 2025 and vested in full one year later, delivering common shares to the director on a one-for-one basis. Following this transaction, Hillson directly holds 3,430 shares of Eledon Pharmaceuticals common stock.
Eledon Pharmaceuticals director Allan Kirk reported acquiring common shares through the vesting of equity awards. On January 10, 2026, 3,430 restricted stock units (RSUs) that had been granted on January 10, 2025 vested in full and were settled into 3,430 shares of Eledon Pharmaceuticals common stock on a one-for-one basis.
The RSU settlement was reported at a price of $0 per share, reflecting that no cash was paid in this conversion. Following the transaction, Allan Kirk beneficially owned 3,430 shares of common stock directly.
Eledon Pharmaceuticals director Keith Katkin reported the vesting and settlement of restricted stock units into common shares. On January 10, 2026, 8,575 restricted stock units converted into 8,575 shares of Eledon Pharmaceuticals common stock at a price of $0 per share, reflected as a transaction coded "M". These RSUs were originally granted on January 10, 2025 and vested 100% on January 10, 2026. Following the transaction, Katkin beneficially owned 8,575 shares of common stock directly.
Eledon Pharmaceuticals director June Lee reported the vesting and settlement of restricted stock units into common shares. On January 10, 2026, 3,430 restricted stock units converted into 3,430 shares of common stock at a price of $0 per share, leaving Lee with 3,430 common shares held directly after the transaction.
The footnote explains that these shares came from restricted stock units granted on January 10, 2025, which vested 100% on January 10, 2026 on a one-for-one basis into common stock. Following the conversion, the derivative position in these restricted stock units was reduced to zero.
Eledon Pharmaceuticals director reports RSU vesting and share settlement. Director James A. Robinson Jr. settled 3,430 restricted stock units (RSUs) into 3,430 shares of common stock on January 10, 2026, in a transaction coded "M" at a price of $0 per share. The RSUs were originally granted on January 10, 2025 and vested 100% on January 10, 2026.
Following this settlement, Robinson directly holds 3,430 shares of Eledon Pharmaceuticals common stock. The derivative position in the RSUs reported in this filing is now shown as 0 derivative securities beneficially owned, reflecting the full conversion into common shares.
Eledon Pharmaceuticals reports a Q3 2025 net loss of $17.5 million, driven by $19.1 million of operating expenses, mainly research and development on its lead anti-CD40L antibody tegoprubart. For the first nine months of 2025, the net loss was $35.2 million on $61.8 million of operating expenses, reflecting heavier R&D investment versus 2024.
At September 30, 2025, Eledon held $3.7 million in cash and cash equivalents and $89.7 million in short-term investments, for total liquid resources of $93.4 million and working capital of $82.0 million. Management believes this is sufficient to fund planned operations for at least 12 months from the filing date, while noting that additional financing will be needed to support longer-term plans.
Warrant liabilities declined to $21.9 million from $44.9 million at year-end 2024, producing a $22.9 million non-cash gain over nine months. The company also restated prior financial statements to treat its Series X and X1 non-voting convertible preferred stock as a separate class for earnings per share and to classify it as temporary equity due to certain contingent redemption features.
Eledon Pharmaceuticals announced an underwritten public offering of 15,152,485 shares of common stock at $1.65 per share and pre-funded warrants priced at $1.649 each, exercisable for up to 15,151,515 shares at an exercise price of $0.001 per share.
The underwriters have a 30‑day option to purchase up to 4,545,600 additional shares. Estimated net proceeds to the company are approximately $46.5 million, or $53.6 million if the option is exercised in full. Closing is expected on November 13, 2025, subject to customary conditions. Eledon plans to use proceeds to support continued clinical development, advance pipeline programs, and for general corporate purposes.
Certain officers and directors agreed to 60‑day lock‑ups from November 12, 2025. Pre‑funded warrants include a beneficial ownership cap of 4.99% (or 9.99% at holder election), adjustable with 61 days’ notice, not to exceed 19.99% to comply with Nasdaq rules.
Eledon Pharmaceuticals (ELDN) launched a primary offering of 15,152,485 shares and pre‑funded warrants to purchase up to 15,151,515 shares. The public offering price is $1.65 per share and $1.649 per pre‑funded warrant, with warrant exercise price of $0.001 per share. Gross proceeds are $49,986,448, less $3,000,096 in underwriting discounts, for proceeds to the company of $46,986,352 before expenses. The underwriters have a 30‑day option to buy up to 4,545,600 additional shares.
The company estimates net proceeds of approximately $46.5 million (or about $53.6 million if the option is fully exercised), to fund continued clinical development and general corporate purposes. Pre‑funded warrants are not listed and include a 4.99% (or 9.99% at holder’s election) beneficial ownership cap. Shares outstanding were 59,881,775 as of June 30, 2025; this is a baseline figure, not the amount being offered.